Additionally, Reuters forecasts an increase in IPOs after the summer for biotech companies with proven value backed by positive data from clinical trials. (Source: Reuters, June 2023).
Currently, many medicine companies are undervalued in the stock market. In particular, those companies that are well-funded and have a broad pipeline of breakthrough medicines have an exciting investment potential. Especially if they are companies developing medicines for conditions for which no (good) treatment exists yet. Thanks to new technologies such as gene, RNA and cell therapy, we can now treat many more diseases than before.
88 such Genetics medicines are already on the market. 2.000 are in development of which 200 are in the final clinical phase. The Genetics companies developing these therapies have a great opportunity to generate significant returns for investors. Especially as their innovative medicines move towards approval and sales.